CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...

ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in phlebotomy requirements through 52 weeks in patients with polycythemia vera (PV), ...

Rusfertide may eliminate therapeutic phlebotomies in polycythemia vera, showing symptomatic improvement and potential treatment utility. Besremi outperformed anagrelide in essential thrombocythemia, ...

The archaic practice of removing blood from the body to treat a wide range of illnesses lives on today as a standard treatment for certain blood disorders. The modern version of this approach, called ...

Please provide your email address to receive an email when new articles are posted on . Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit ...

Please provide your email address to receive an email when new articles are posted on . Rusfertide reduced need for phlebotomies and offered better hematocrit control than placebo. Results showed ...

PV management requires balancing thrombotic risk reduction with quality of life preservation, often involving trade-offs. JAK/STAT pathway activation contributes to chronic inflammation and symptom ...

Phlebotomy refers to drawing blood from a person’s vein with a needle. Lab tests on blood samples are important as they measure different blood components and provide information that can lead to a ...